These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25379273)

  • 1. Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.
    Boules MM; Fredrickson P; Muehlmann AM; Richelson E
    Behav Sci (Basel); 2014 Jun; 4(2):125-153. PubMed ID: 25379273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotensin agonists: potential in the treatment of schizophrenia.
    Boules M; Shaw A; Fredrickson P; Richelson E
    CNS Drugs; 2007; 21(1):13-23. PubMed ID: 17190526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotensin, schizophrenia, and antipsychotic drug action.
    Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactive analogs of neurotensin: focus on CNS effects.
    Boules M; Fredrickson P; Richelson E
    Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel treatments of schizophrenia: targeting the neurotensin system.
    Kinkead B; Nemeroff CB
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin agonists as an alternative to antipsychotics.
    Boules M; Fredrickson P; Richelson E
    Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
    Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions.
    Kasckow J; Nemeroff CB
    Regul Pept; 1991 Oct; 36(2):153-64. PubMed ID: 1666685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse roles of neurotensin agonists in the central nervous system.
    Boules M; Li Z; Smith K; Fredrickson P; Richelson E
    Front Endocrinol (Lausanne); 2013; 4():36. PubMed ID: 23526754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
    Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
    Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.
    Li Z; Boules M; Williams K; Peris J; Richelson E
    Brain Res; 2010 Jan; 1311():28-36. PubMed ID: 19948149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin: role in psychiatric and neurological diseases.
    Cáceda R; Kinkead B; Nemeroff CB
    Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current topics: brain penetrating neurotensin analog.
    Boules M; Fredrickson P; Richelson E
    Life Sci; 2003 Oct; 73(22):2785-92. PubMed ID: 14511764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotensin: an endogenous antipsychotic?
    Kinkead B; Nemeroff CB
    Curr Opin Pharmacol; 2002 Feb; 2(1):99-103. PubMed ID: 11786316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The electrophysiological actions of neurotensin in the central nervous system.
    Stowe ZN; Nemeroff CB
    Life Sci; 1991; 49(14):987-1002. PubMed ID: 1890928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopamine receptor plasticity in neurotensin deficient mice.
    Chastain LG; Qu H; Bourke CH; Iuvone PM; Dobner PR; Nemeroff CB; Kinkead B
    Behav Brain Res; 2015 Mar; 280():160-71. PubMed ID: 25449842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
    Gruber SH; Nomikos GG; Mathé AA
    Eur Neuropsychopharmacol; 2006 Dec; 16(8):592-600. PubMed ID: 16524702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.